Who is sponsoring NCT03153163?

NCT03153163 is sponsored by Hoffmann-La Roche.

What condition does NCT03153163 study?

NCT03153163 studies Breast Neoplasms.

What drugs are being tested in NCT03153163?

Interventions: Trastuzumab Emtansine.

What is the status of NCT03153163?

NCT03153163 is currently COMPLETED.

Last reviewed 2018-11-23 · How we verify

Study of the Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Participants With Locally Advanced Inoperable or Metastatic HER2+ Breast Cancer

NCT03153163 PHASE1 COMPLETED

This is an open-label Phase I study of single-agent trastuzumab emtansine administered by intravenous (IV) infusion. The study will characterize the pharmacokinetics of trastuzumab emtansine and its relevant analytes and the safety of trastuzumab emtansine in Chinese participants with human epidermal growth factor receptor 2 (HER2)-positive locally advanced/metastatic breast cancer (LA/MBC).

Details

Lead sponsor	Hoffmann-La Roche
Phase	PHASE1
Status	COMPLETED
Enrolment	11
Start date	Tue Jun 20 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Sep 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Breast Neoplasms

Interventions

Trastuzumab Emtansine

Countries

China